Johnson & Johnson (NYSE:JNJ) Stock Unloaded Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on February 19th, the Representative disclosed that they had sold between $15,001 and $50,000 in Johnson & Johnson stock on January 23rd. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/29/2026.
• Sold $15,001 – $50,000 in shares of Stryker (NYSE:SYK) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/23/2026.
• Sold $15,001 – $50,000 in shares of Markel Group (NYSE:MKL) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of General Motors (NYSE:GM) on 1/7/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/26/2025.

Johnson & Johnson Stock Down 0.1%

Shares of NYSE JNJ traded down $0.17 during mid-day trading on Tuesday, reaching $245.67. 3,299,448 shares of the company’s stock were exchanged, compared to its average volume of 9,362,563. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $247.25. The business has a fifty day simple moving average of $221.69 and a 200 day simple moving average of $199.96. The firm has a market capitalization of $592.04 billion, a price-to-earnings ratio of 22.23, a PEG ratio of 2.35 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Institutional Trading of Johnson & Johnson

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Trading Solutions LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $2,391,000. Nolet Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $499,000. Investment Insight Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $345,000. Lynch Investment Planning LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $262,000. Finally, Clear Retirement Advice LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $224,000. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 in the last three months. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Rothschild & Co Redburn lifted their target price on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Wolfe Research upped their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Royal Bank Of Canada lifted their price target on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, Morgan Stanley set a $262.00 price target on Johnson & Johnson and gave the company an “overweight” rating in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $232.70.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Long‑term TREMFYA data bolster JNJ’s immunology growth thesis — three‑year ulcerative colitis results showed sustained outcomes, supporting revenue forecasts and valuation upside for the Pharmaceuticals division. Johnson & Johnson presents three-year TREMFYA data showing sustained ulcerative colitis outcomes
• Positive Sentiment: Potential sale of DePuy Synthes could unlock large cash proceeds and simplify the company — reports that J&J is exploring a mega sale as part of its orthopedics separation are being priced as value‑accretive by investors. J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push
• Positive Sentiment: Broader momentum: analysts and outlets cite a “triple threat” (oncology growth, MedTech rebound, and an earnings beat) that explains recent outperformance and investor rotation into defensive, cash‑generating names. Does JNJ Stock Still Offer Value?
• Neutral Sentiment: Analyst commentary is broadly positive but cautious — several firms maintain buy/overweight views while some trim enthusiasm, creating mixed signals rather than a clear directional catalyst. Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?
• Neutral Sentiment: Strategic partnerships and corporate moves (first co‑funding with Blackstone) are long‑term strategic steps; short‑term market impact has been muted pending deal details. Johnson & Johnson (JNJ) Stock Flat despite First Co-funding Agreement with Blackstone
• Neutral Sentiment: Dividend mechanics: the stock went ex‑dividend this period ($1.30 payout), a mechanical factor that can cause a one‑day price adjustment but isn’t a fundamental change. Johnson & Johnson Price & Dividend Details
• Negative Sentiment: Bayer lawsuit over prostate‑cancer drug claims increases legal/regulatory uncertainty for the Janssen unit and could lead to costs or marketing restrictions if resolved unfavorably. Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
• Negative Sentiment: Insider selling disclosed: EVP Timothy Schmid sold shares (Form 4 filings), a routine liquidity event but one some investors interpret as profit‑taking and it can weigh on sentiment. SEC filing: Form 4 — Timothy Schmid sale

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.